The detailed information for PTAB case with proceeding number IPR2019-00686 filed by Nalox-1 Pharmaceuticals, LLC et al. against Opiant Pharmaceuticals, Inc. on Feb 19, 2019. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2019-00686
Filing Date
Feb 19, 2019
Petitioner
Nalox-1 Pharmaceuticals, LLC et al.
Respondent
Opiant Pharmaceuticals, Inc.
Status
Institution Denied
Respondent Application Number
14659472
Respondent Tech Center
1600
Respondent Patent Number
9211253
Institution Decision Date
Aug 27, 2019

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Notice of Refund

Oct 21, 2019PAPERBOARD

PETITIONER NALOX-1 PHARMACEUTICALS, LLC¿¿¿S REQUEST FOR REFUND OF POST-INSTITUTION FEES

Oct 3, 2019PAPERPETITIONER

Denying Institution of Inter Partes Review 35 U.S.C. sec. 314(a)

Aug 27, 2019PAPERBOARD

PATENT OWNER'S NOTICE OF TRIAL DATE IN THE TEVA CASE

Jul 22, 2019PAPERPATENT OWNER

PATENT OWNER'S RESPONSE TO PETITIONER'S NOTICE

Jun 24, 2019PAPERPATENT OWNER

Petitioner's Notice of Rankings

Jun 17, 2019PAPERPETITIONER

Conduct of the Proceeding

Jun 11, 2019PAPERBOARD

Opiant2001 Williams Decl

May 28, 2019EXHIBITPATENT OWNER

Opiant2003 Aquina 2009

May 28, 2019EXHIBITPATENT OWNER

Opiant2004 Baca 2005

May 28, 2019EXHIBITPATENT OWNER

Opiant2005 Belz 2006

May 28, 2019EXHIBITPATENT OWNER

Opiant2006 Buajordet 2004

May 28, 2019EXHIBITPATENT OWNER

Opiant2002 Amphastar Press Release

May 28, 2019EXHIBITPATENT OWNER

Opiant2009 FDA Teva Press Release

May 28, 2019EXHIBITPATENT OWNER

Opiant2011 Goldfranks

May 28, 2019EXHIBITPATENT OWNER

Opiant2012 Indivior Press Release

May 28, 2019EXHIBITPATENT OWNER

Opiant2015 Loimer 1992

May 28, 2019EXHIBITPATENT OWNER

Opiant2017 Osterwalder 1996

May 28, 2019EXHIBITPATENT OWNER

Opiant2018 Pallasch 1981

May 28, 2019EXHIBITPATENT OWNER

Opiant2019 Popper 1989

May 28, 2019EXHIBITPATENT OWNER

Opiant2025 Teva Case Claim Construction Opinion

May 28, 2019EXHIBITPATENT OWNER

Opiant2007 Burford Press Release

May 28, 2019EXHIBITPATENT OWNER

Opiant2008 EVZIO Prescribing Information

May 28, 2019EXHIBITPATENT OWNER

Opiant2010 Gaddis 1992

May 28, 2019EXHIBITPATENT OWNER

Opiant2013 Kelly 2002

May 28, 2019EXHIBITPATENT OWNER

Opiant2014 Letter from Ten Congressmen

May 28, 2019EXHIBITPATENT OWNER

Opiant2016 Narcan Nasal Spray Prescribing Information

May 28, 2019EXHIBITPATENT OWNER

Opiant2020 Schwartz 1987

May 28, 2019EXHIBITPATENT OWNER

Opiant2021 Sporer 1996

May 28, 2019EXHIBITPATENT OWNER

Opiant2022 Sporer 2007

May 28, 2019EXHIBITPATENT OWNER

Opiant2023 Stoove 2009

May 28, 2019EXHIBITPATENT OWNER

Opiant2024 Terman 2012 Slides

May 28, 2019EXHIBITPATENT OWNER

Opiant2026 Teva Case Schedule Stipulation

May 28, 2019EXHIBITPATENT OWNER

Opiant2027 van Dorp 2007

May 28, 2019EXHIBITPATENT OWNER

Opiant2028 Walley 2013

May 28, 2019EXHIBITPATENT OWNER

Opiant2029 Wermeling 2015

May 28, 2019EXHIBITPATENT OWNER

Opiant2030 Wermeling 354

May 28, 2019EXHIBITPATENT OWNER

Opiant2031 Williams 2019

May 28, 2019EXHIBITPATENT OWNER

Opiant2032 Yealy 1990

May 28, 2019EXHIBITPATENT OWNER

Opiant2033 Zuckerman 2014

May 28, 2019EXHIBITPATENT OWNER

PRELIMINARY RESPONSE OF PATENT OWNER OPIANT PHARMACEUTICALS, INC.

May 28, 2019PAPERPATENT OWNER

MANDATORY NOTICES OF PATENT OWNER OPIANT PHARMACEUTICALS, INC.

Mar 12, 2019PAPERPATENT OWNER

POWER OF ATTORNEY FOR OPIANT PHARMACEUTICALS, INC.

Mar 12, 2019PAPERPATENT OWNER

NOTICE OF FILING DATE ACCORDED TO PETITION AND TIME FOR FILING PATENT OWNER PRELIMINARY RESPONSE

Feb 25, 2019PAPERBOARD

Petition

Feb 19, 2019PAPERPETITIONER

Power of Attorney

Feb 19, 2019PAPERPETITIONER

Nalox1002 Donovan Declaration

Feb 19, 2019EXHIBITPETITIONER

Nalox1003 Hochhaus Declaration

Feb 19, 2019EXHIBITPETITIONER

Nalox1004 FH 15_183,441 Excerpt - Aug. 22, 2016 Action

Feb 19, 2019EXHIBITPETITIONER

Nalox1008 Chinese Patent No. 1,575,795 (Wang) (Paginated Translation)

Feb 19, 2019EXHIBITPETITIONER

Nalox1009 WO 00_62,757 (Davies)

Feb 19, 2019EXHIBITPETITIONER

Nalox1012 Handbook of Pharmaceutical Excipients, selected pages

Feb 19, 2019EXHIBITPETITIONER

Nalox1017 Alabama EMS Protocols (2013)

Feb 19, 2019EXHIBITPETITIONER

Nalox1019 Ashton

Feb 19, 2019EXHIBITPETITIONER

Nalox1020 Barton (2002)

Feb 19, 2019EXHIBITPETITIONER

Nalox1021 Barton (2005)

Feb 19, 2019EXHIBITPETITIONER

Nalox1022 Bitter

Feb 19, 2019EXHIBITPETITIONER

Nalox1024 CDC - Zomig Review

Feb 19, 2019EXHIBITPETITIONER

Nalox1001 U. S. Patent 9,211,253

Feb 19, 2019EXHIBITPETITIONER

Nalox1005 FH 15_183,441 Excerpt - Oct. 21, 2016 Resp.

Feb 19, 2019EXHIBITPETITIONER

Nalox1007 U.S. Patent No. 9,192,570 (Wyse)

Feb 19, 2019EXHIBITPETITIONER

Nalox1010 Djupesland (2013)

Feb 19, 2019EXHIBITPETITIONER

Nalox1011 Grassin-Delyle (2012)

Feb 19, 2019EXHIBITPETITIONER

Nalox1013 Kushwaha (2011)

Feb 19, 2019EXHIBITPETITIONER

Nalox1014 U.S. Patent No. 5,866,154 (Bahal)

Feb 19, 2019EXHIBITPETITIONER

Nalox1015 U.S. Patent No. 8,198,291

Feb 19, 2019EXHIBITPETITIONER

Nalox1016 Wermeling (2013)

Feb 19, 2019EXHIBITPETITIONER

Nalox1018 APTAR Press Release

Feb 19, 2019EXHIBITPETITIONER

Nalox1023 Boyer

Feb 19, 2019EXHIBITPETITIONER

Nalox1025 Commonwealth Kentucky Patient Care Protocols (2015)

Feb 19, 2019EXHIBITPETITIONER

Nalox1029 2003 FDA Guidance

Feb 19, 2019EXHIBITPETITIONER

Nalox1032 Hertz Presentation

Feb 19, 2019EXHIBITPETITIONER

Nalox1034 Kelly

Feb 19, 2019EXHIBITPETITIONER

Nalox1035 Kerr (2008)

Feb 19, 2019EXHIBITPETITIONER

Nalox1036 Kerr (2009)

Feb 19, 2019EXHIBITPETITIONER

Nalox1039 Merck Index (47-60)

Feb 19, 2019EXHIBITPETITIONER

Nalox1026 Costantino

Feb 19, 2019EXHIBITPETITIONER

Nalox1027 Dowling

Feb 19, 2019EXHIBITPETITIONER

Nalox1028 2002 FDA Guidance

Feb 19, 2019EXHIBITPETITIONER

Nalox1030 Freise

Feb 19, 2019EXHIBITPETITIONER

Nalox1031 Glende

Feb 19, 2019EXHIBITPETITIONER

Nalox1037 Kleiman-Wexler

Feb 19, 2019EXHIBITPETITIONER

Nalox1038 Marple

Feb 19, 2019EXHIBITPETITIONER

Nalox1041 Middleton

Feb 19, 2019EXHIBITPETITIONER

Nalox1042 Monitto

Feb 19, 2019EXHIBITPETITIONER

Nalox1044 PDR (2003)

Feb 19, 2019EXHIBITPETITIONER

Nalox1048 Role of Naloxone (76 Fed Reg. 71,348)

Feb 19, 2019EXHIBITPETITIONER

Nalox1050 Rosanske

Feb 19, 2019EXHIBITPETITIONER

Nalox1053 Trows

Feb 19, 2019EXHIBITPETITIONER

Nalox1054 USP 36-NF 31

Feb 19, 2019EXHIBITPETITIONER

Nalox1055 U.S. Patent Appl. No. 61_918,802

Feb 19, 2019EXHIBITPETITIONER

Nalox1056 U.S. Patent No. 5,307,953

Feb 19, 2019EXHIBITPETITIONER

Nalox1057 U.S. Patent No. 5,813,570

Feb 19, 2019EXHIBITPETITIONER

Nalox1059 Wermeling (2010)

Feb 19, 2019EXHIBITPETITIONER

Nalox1060 Loimer

Feb 19, 2019EXHIBITPETITIONER

Nalox1061 Doe-Simkins

Feb 19, 2019EXHIBITPETITIONER

Nalox1040 Merlin

Feb 19, 2019EXHIBITPETITIONER

Nalox1043 Lemke

Feb 19, 2019EXHIBITPETITIONER

Nalox1045 PDR (2010)

Feb 19, 2019EXHIBITPETITIONER

Nalox1046 Robertson (2005)

Feb 19, 2019EXHIBITPETITIONER

Nalox1047 Robertson (2009)

Feb 19, 2019EXHIBITPETITIONER

Nalox1049 Role of Naloxone (Full Transcript), 2012.04.12

Feb 19, 2019EXHIBITPETITIONER

Nalox1051 Sabzghabaee

Feb 19, 2019EXHIBITPETITIONER

Nalox1058 U.S. Provisional Patent App. 61_953379

Feb 19, 2019EXHIBITPETITIONER

Nalox1062 McDermott

Feb 19, 2019EXHIBITPETITIONER

Nalox1064 Butler

Feb 19, 2019EXHIBITPETITIONER

Nalox1065 Wisconsin - part 2

Feb 19, 2019EXHIBITPETITIONER

Nalox1065 Wisconsin - part 1

Feb 19, 2019EXHIBITPETITIONER

Nalox1066 Lipscomb

Feb 19, 2019EXHIBITPETITIONER

Nalox1006 FH 15_183,441 Excerpt - Dec. 21, 2016 NOA

Feb 19, 2019EXHIBITPETITIONER